Patent ID: 11879013
Assignee: JANSSEN BIOTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 9:
10. The method of claim 9, wherein the EGFR mutation is E709K, L718Q L718V, G719A, G719X, G724X, G724S, I744T, E746K, L747S, E749Q, A750P A755V, V765M, C775Y, T790M, L792H, L792V, G796S G796C, C797S, T854I, L858P L858R, L861X, delE746-A, 750 delE746_T751InsKV, delE746_A750InsHS, delE746_T751InsFPT, delE746_T751InsL, delE746_S752InsIP, delE746_P753InsMS, delE746_T751InsA, delE746_T751InsAPT, delE746_T751InsVA, delE746_S752InsV, delE746_P753InsVS, delE746_K754InsGG, delE746_E749, delE746_delL747_E749, delL747_A750InsP, delL747_T751InsP, delL747_T751InsN, delL747_S752InsPT, delL747_P753InsNS, delL747_S752InsPI, delL747_delL747_P753InsS, delL747_K754, dekL747_T751InsS, dekL747_delL747_P753InsS, delA750_1759InsPT, delT751_1759InsT, delS752_1759, delT751_1759InsN, delT751_D761InsNLY, delS752_1759, delR748-P753, delL747-P753InsS, delL747-T751, M766_A767InsA, S768_V769InsSVA, P772_H773InsNS, D761_E762InsX1-7, A763_Y764InsX1-7, Y764_Y765 InsX1-7, M766_A767InsX1-7, A767_V768 InsX1-7, S768_V769 InsX1-7, V769_D770 InsX1-7, D770_N771 InsX1-7, N771_P772 InsX1-7, P772_H773 InsX1-7, H773_V774 InsX1-7, V774_C775 InsX1-7, one or more deletions in EGFR exon 20, or one or more insertions in EGFR exon 20, one or more deletions in EGFR exon 19, or one or more insertions in EGFR exon 19, or any combination thereof, wherein X is any amino acids.